For instance, IL-6 blockade via monoclonal antibodies or JAK/STAT3 inhibitors has demonstrated early promise in solid tumors, including cervical cancer, by reducing proliferation, reversing EMT, and sensitizing tumor cells to chemotherapy and radiotherapy. This evidence concerns the gene IL6 and cervical cancer.